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Abstract 
The wave of next-generation sequencing data has arrived. However, many questions still remain about 
how to best analyze sequence data, particularly the contribution of rare genetic variants to human 
disease. Numerous statistical methods have been proposed to aggregate association signals across 
multiple rare variant sites in an effort to increase statistical power; however, the precise relation between 
the tests is often not well understood. We present a geometric representation for rare variant data in 
which rare allele counts in case and control samples are treated as vectors in Euclidean space. The 
geometric framework facilitates a rigorous classification of existing rare variant tests into two broad 
categories: tests for a difference in the lengths of the case and control vectors, and joint tests for a 
difference in either the lengths or angles of the two vectors. We demonstrate that genetic architecture of 
a trait, including the number and frequency of risk alleles, directly relates to the behavior of the length and 
joint tests. Hence, the geometric framework allows prediction of which tests will perform best under 
different disease models. Furthermore, the structure of the geometric framework immediately suggests 
additional classes and types of rare variant tests. We consider two general classes of tests which show 
robustness to noncausal and protective variants. The geometric framework introduces a novel and unique 
method to assess current rare variant methodology and provides guidelines for both applied and 
theoretical researchers. 
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The wave of next-generation sequencing data has arrived. However, many questions still remain about how to best 
analyze sequence data, particularly the contribution of rare genetic variants to human disease. Numerous  statistical 
methods have been proposed to aggregate association signals across multiple rare variant sites in an effort to 
increase statistical power; however, the precise relation between the tests is often not well understood. We present a 
geometric representation for rare variant data in which rare allele counts in case and control samples are treated as 
vectors in Euclidean space. The geometric framework facilitates a rigorous classification of existing rare variant 
tests into two broad categories: tests for a difference in the lengths of the case and control vectors, and joint tests for 
a difference in either the lengths or angles of the two vectors. We demonstrate that genetic architecture of a trait, 
including the number and frequency of risk alleles, directly relates to the behavior of the length and joint tests. 
Hence, the geometric framework allows prediction of which tests will perform best under different disease models. 
Furthermore, the structure of the geometric framework immediately suggests additional classes and types of rare 
variant tests. We consider two general classes of tests which show robustness to non-causal and protective variants. 
The geometric framework introduces a novel and unique method to assess current rare variant methodology and 
provides guidelines for both applied and theoretical researchers. 






Several large sequencing efforts have established that an abundance of rare functional variation exists in the human 
population [1000 Genomes 2010; Nelson et al., 2012; Tennessen et al., 2012].  The preponderance of such variants 
and their potential deleterious impact make them candidates for putative risk variants contributing to complex 
disease in humans. Thus, the development of powerful statistical methods to analyze these rare genetic variants 
observed in next-generation sequencing data is a critical area of current research in human genetics.  Traditional 
single marker tests used in genome-wide association studies (GWAS) lack sufficient power when applied to rare 
variants. Instead, many novel “gene-based” methods have been proposed with a common theme of combining 
association signals for multiple rare variants from the same gene into a single test of significance [Morgenthaler and 
Thilly, 2007; Li and Leal, 2008; Madsen and Browning 2009; Morris and Zeggini 2010; Zawistowski et al., 2010; 
Han and Pan, 2010; Price et al., 2010; Neale et al., 2011; Wu et al., 2011; Basu and Pan, 2011; Lin and Tang, 2011; 
Pan and Shen, 2011; Ionita-Laza et al. 2011, Feng et al., 2011, Zhang et al., 2011; Sul et al., 2011; Li et al., 2011; 
Dai et al., 2012, among others].  Several summaries and reviews of these methods are available [Asimit and Zeggini, 
2010, Bansal et al. 2010, Dering et al. 2011, Cooper and Shendure 2011, Gibson 2012]. 
 
As reflected by the number and variety of proposed gene-based methods, there is no clear-cut strategy to combine 
the information from multiple sites into a single test statistic. The existing methods differ not only in how individual 
variants are summarized and weighted before being combined but also the assumptions on the underlying disease 
model. Not surprisingly, the performance varies dramatically among proposed methods. The consensus among 
several simulation based studies comparing performance between the gene-based tests is that there is no single best 
strategy for testing rare variants [e.g., Ladouceur et al. 2012, Basu and Pan 2011, Tintle et al. 2011, Luedtke et al. 
2011, Sun et al. 2011].  Differences in the underlying disease models on which simulations are based, including 
frequency spectrum and effect sizes for risk variants, as well as analytic challenges such as inclusion of neutral 
variants all directly impact test performance.  However, the severity of the effect differs amongst the proposed tests. 
Although the results of these simulation studies show that different tests are optimal for different scenarios, we often 
lack an intuitive understanding as to why certain methods perform the way that they do. For example, Basu and Pan 
[2011], after conducting an extremely comprehensive simulation study, conclude that while a particular variance 
components test appears to be the “best” across a variety of disease models, the result is “surprising and interesting.”   
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Further complicating matters is that there have been relatively few published applications of gene-based rare variant 
tests on real data [e.g., Rivas et al. 2011, Torgerson et al. 2012], leaving us unsure about what types of rare variant 
genetic architectures exist in nature.  
 
To address some of the gaps in our understanding of rare variant test performance, we introduce a novel framework 
for considering such tests. Specifically, we consider case-control sequence data as mathematical vectors in a 
geometric space and relate differences in rare variation between cases and controls to differences in the lengths and 
angles of vectors. Based on this geometric framework, we show that the null hypothesis of no association that is 
tested in gene-based rare variant tests can be decomposed into a compound geometric null hypothesis based on the 
lengths and angle between the vectors representing the case and control data. The geometric framework allows an 
intuitive classification of many existing tests into broad categories based on which portion of the compound null 
hypothesis is being tested. We show that within these categories, the general performance of individual tests is well 
predicted by the geometric properties of the case and control vectors. In turn, we describe how aspects of the 
underlying disease model and study conditions affect the geometry of the dataset, thus connecting test behavior to 
these more traditional study variables. We verify these analytic insights using simulation.  
 
The main benefit of the geometric framework is that it provides a rigorous method with which to categorize existing 
rare variant tests. The classification helps to explain why certain tests perform more similarly than others and 
provides a means to evaluate new tests that are certain to be proposed in the future. In addition to a classification 
scheme, the geometric framework suggests additional tests of rare variant association unlike tests proposed to date. 
In particular, existing tests can be combined or modified to respond more optimally to differing distributions of 
neutral, risk and protective variants. 
 
Methods 
I. The geometric framework  
Assume a dataset consisting of sequence information for a gene of interest in   cases and   controls. We restrict 
attention to a subset of m variable sites in the dataset that are putative risk variants satisfying some predefined minor 
allele frequency (   ) threshold and predicted functional annotation, for example       and 
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nonsynonymous. Let   
  be the total number of rare alleles observed at site         among the cases. Similarly, 
let   
  be the total number of rare alleles observed at site         among the controls. Then we define    
(  
      
 ) to be the vector of maximum likelihood estimates of allele frequencies in cases at the m sites of interest, 
where   
    
     . Likewise, define    in the same manner for controls. 
 
Assuming no genotype-phenotype association at the jth site leads to the familiar single marker null hypothesis of 
equal allele frequency in the populations of cases and controls, namely   
    
 , where we let    be the population 
minor allele frequency at site j.  Assuming the null hypothesis of no association holds for all m variable sites 
observed in the dataset, the null hypothesis that rare, putatively functional observed variation in the gene is not 
associated with disease risk can be formally stated as 
    
     <eq. 1> 
Now, consider    and    as mathematical vectors in m-dimensional space. Two vectors are equivalent if and only if 
both their magnitudes (lengths) and directions (angles) are equal. Thus, the null hypothesis       in <eq. 1> is 
equivalent to the geometric compound null hypothesis, 
    ‖ 
 ‖  ‖ 
 ‖  and      <eq. 2> 
where ‖ ‖   (∑ |  |
  
   )
 
 ⁄ , p ≥1, denotes the Lp norm of a vector   (         ) and 
         (
     
‖  ‖  ‖ 
 ‖ 
)  is the angle between the vectors   and   .  In order to show that the null hypothesis in 
<eq. 2> does not hold it is sufficient to show that either  ‖  ‖  ‖ 
 ‖  or    . Thus, the null hypotheses 
            ‖ 
 ‖  ‖ 
 ‖  and <eq. 3> 
            <eq. 4> 
are both necessary but not individually sufficient in order for <eq. 1> to hold.  
 
Alternatively, two vectors are equivalent if the difference vector that connects their endpoints is the zero vector, in 
this case       (  
    
      
    
 ).  Thus, a further reformulation of <eq. 1> is  
    
      . <eq. 5> 
Since a vector     if and only if ‖ ‖   , it is sufficient to show that ‖ 
    ‖    in order to show that 
<eq. 3> does not hold. Therefore  
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          ‖ 
    ‖    <eq. 6> 
is equivalent to <eq. 1> and we refer to it as the joint null hypothesis since the difference vector       jointly 
accounts for both the lengths and angle of the frequency vectors   and   . This is further illustrated by the fact that 
for L2  
‖     ‖ 
  (‖  ‖  ‖ 
 ‖ )
    ‖  ‖  ‖ 
 ‖  (      ( )) <eq. 7> 
Essentially, <eq.7> combines a comparison of the differences in the lengths of the two vectors   and    with an 
evaluation of the size of the angle,  , observed between   and   . Figure 1 gives a graphical rendering of the 
geometric framework in order to provide visual intuition about the behavior of length, joint and angle tests. 
 
In the following sections, we show that many rare variant tests of the null hypothesis     
     can be formally 
classified according to which geometric null hypothesis (eqs. 3, 4 or 6) is being tested (see Table 1).  
 
A. Length Tests 
We refer to rare variant tests of the null hypothesis             ‖ 
 ‖  ‖ 
 ‖  as length tests. Here we show two 
examples of published statistics that are length tests. The cumulative minor allele test [CMAT; Zawistowski et al. 
2010] compares the total number of minor and major alleles in cases and controls across rare, functional variants 
within the same gene. Using our notation, the test statistic for CMAT is       
 
      
  (      )   (      )
(     )(             )
, 
where    ∑   
  
   , which can be simplified to        (‖ 
 ‖  ‖ 
 ‖ ), where k is a function of 
                    . The CMAT statistic is significant (as determined by permutation) when      , and 
therefore ‖  ‖  ‖ 
 ‖   becomes large. 
 
Proportion regression [PR; Morris and Zeggini, 2010] uses a logistic regression framework to test for a rare variant 
association. Specifically, PR uses the model      (  )       
  
 
 where    is a vector of p covariate values for 
the     individual, α is the vector of marginal effects of the p covariates on the disease phenotype and    ∑    
 
    
is the total number of rare alleles possessed by the     individual across the m variants. The score statistic   
(   ̂ )
    (   ̂ ) is used to test       , where y is a length N vector (N=total number of individuals in the 
study) of 0s and 1s, where 1=the individual is a case, 0 otherwise,  ̂  is a vector of predicted disease probabilities 
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estimated under the null logistic model, and   is a vector containing    ⁄  for each of the   individuals in the study. 
Under the null hypothesis of no association (<eq. 1>), S is distributed as a one degree of freedom chi-squared 
random variable. For simplicity, consider the case of no covariates and an equal number of cases and controls, which 
yields  ̂  
 
 
 for all individuals. Then the PR score statistic can be written in terms of the vector length as follows 
  (   ̂ )
    (   ̂ )   (   ̂ )
    (   ̂ ) 
    (    )    (    ) 
    (      (   ))
 




(‖  ‖  ‖ 
 ‖ )
  
The null hypothesis         will be rejected for large S, which occurs when  ‖ 
 ‖  ‖ 
 ‖   
 
We identified a total of twelve recently proposed rare variant tests as length tests based on the fact that significance 
of the test statistics was equivalent to testing  ‖  ‖  ‖ 
 ‖  (Appendix 1).  Many length tests have been referred 
to in the literature as “burden” tests or “collapsing” tests [e.g., Dering et al. 2011]. In general, length tests measure 
how rare an individual is based on some index of the individual’s cumulative rare allele profile across all variants in 
the set. This can be viewed as measuring the overall disease “burden” or as “collapsing” all variants in the set. The 
aggregate level of burden within the cases is then compared to the aggregate burden in the controls to test for 
association.  
 
B. Angle Tests 
Tests of the null hypothesis             are referred to as angle tests. To the best of our knowledge, no rare 
variant tests of this specific null hypothesis have been proposed. This is not necessarily a surprising observation 
because, as shown in Figure 1, if the case allele frequency vector,     is a scalar multiple of the control allele 
frequency vector,   , as is the case when there is a consistent level of increased risk (the scalar multiple) across the 
set of variants, there will be no angle between the two vectors. 
 
C. Joint Tests 
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We refer to rare variant tests of the null hypothesis           ‖ 
    ‖    as joint tests since they jointly 
consider both the lengths and angles of the observed frequency vectors   and      A common example of a joint test 
is the Sequence Kernel Association Tests [SKAT, Wu et al. 2011].  Using a scaled version of SKAT with a linear 
unweighted kernel, we see that the test statistic is (   ̂  )
    (   ̂  )   (
 
(  )(  )
)
 
(   ̂  )
    (  
 ̂  ) where A is an N x m genotype matrix containing the rare allele count of each individual at each site, y is an Nx1 
vector indicating disease status (1 or 0) and  ̂   the fraction of cases in the sample. We note that (
 




 ̂  )






(   ))
 






(   ))  (     ) (     )  ‖     ‖ 
    
Using similar rationale we classified six additional rare variant tests as joint tests (Appendix 2).  Appendix 2 also 
illustrates how SKAT can be considered as a joint test for many, but not all, kernel choices. 
 
Unlike length tests, joint tests do not “collapse” or measure the overall individual disease burden in cases as 
compared to controls. Instead joint tests, by evaluating the length of the difference between the case and control 
vectors, consider differences in case-control allele frequency on a variant-by-variant basis, and then combine the 
variant-by-variant differences to obtain a statistic. 
 
D. Novel tests suggested by the geometric framework 
In addition to providing clarity on existing tests of association, the geometric framework also suggests alternative 
rare variant tests of association. In the following two sections we describe two alternative, generalized classes of rare 
variant tests of association that are direct implications of the geometric framework. 
 
Alternative choice of norm 
As shown in the previous sections many length tests use p=1, while most joint tests use p=2. While these choices are 
natural due to asymptotic theory of resulting test statistics and typical conceptualizations of geometric spaces, the 
geometric framework suggests that the choice of norm, p, in ‖ ‖  does not necessarily need to take values of 1 or 2. 
In particular, we can select any positive value for p, including infinity, ∞, where we define ‖ ‖         (  ). 
Thus, we define the following generalized length (Lp) and joint (Jp) test statistics, with arbitrary choice of norm, p, 
as    ‖ 
 ‖  ‖ 
 ‖  and    ‖ 
    ‖ . Appendix 3 provides an overview of how to modify    and    to 
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handle covariates. Statistical significance is assessed via disease permutation. Note that L1 is approximately 
equivalent to CMAT and J2 is approximately equivalent to SKAT. 
 
Weighted length-angle test 
Another way the geometric framework can be used to generate new rare variant tests is by recognizing that length 
and angle tests represent two “extremes” in rare variant testing strategies. As noted earlier joint tests of the form 
‖     ‖  weight the “length” and “angle” portions of the test statistic approximately equally. This is a 
reasonable, though not necessary, choice. We define the following generalized joint test statistic, W, which gives the 
ability to increase or decrease the length or angle portion of the test by modifying   , as well as giving control over 
the choice of norm used through choice of  p and q.  
 (      )    (‖ 
 ‖  ‖ 
 ‖ )
 
 (    )    ‖ 
 ‖  ‖ 
 ‖  (      ( )) 





We use two main simulation studies to validate select findings from our analysis. In the first simulation study we 
simulate 1500 cases and 1500 controls according to the following disease architecture. There are two rare variants in 
the set, each with a minor allele frequency of 1% in the controls in the populations from which the samples are 
selected. The choice of two variants was made to optimally illustrate the behavior of length and joint tests. As we 
will demonstrate later (Results), results easily generalize to any number of variants, m. Variant one has a fixed 
relative risk of 1.25, and we change the relative risk of variant two to take values of 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 
1.6, 1.8, 2.0, 2.5 and 3.0, for a total of 12 separate settings. At each setting we simulated 1000 sets of data. Empirical 
power estimates are calculated as the percentage of the 1000 simulated sets yielding a p-value less than 0.05. Three 
length tests (CMC, CMAT and PR) and two joint tests (SKAT (linear kernel), and C-alpha) were applied to the 
simulated data. Significance was determined by asymptotic distributions or 1000 permutations, depending upon the 
availability of an asymptotic distribution for the test. A smaller follow-up study considered a select set of these 
relative risks (0.2, 0.6, 1.0, 1.4 and 2.0) and applied a weighted length/angle test (described later; Results, C. 




In the second simulation study, we simulated 1000 cases and 1000 controls, according to the following disease 
model. We simulated eight causal variants: two with a minor allele frequency of 1%, and six with a minor allele 
frequency of 0.1% in the populations from which the samples are selected. All eight causal variants have a relative 
risk of 2.0. We then added increasing numbers of non-causal variants (in sets of 8, two at 1%/six at 0.1%). 
Ultimately, we considered 10 different simulation settings representing 0, 8, 16, 24, 32, 40, 48, 56, 64 and 72 non-
causal variants in the set with the eight causal variants. Similar to the first simulation, we simulated 1000 sets of data 




p=1,2,4 or , and four different joint test statistics,  ‖     ‖  with p=1,2,4 or , and where ‖ ‖      (|  |).  
Significance of these eight test statistics was assessed using 1000 permutations of case-control status. 
 
Results 
We have classified the majority of rare variant tests into one of two types: length or joint tests. In the following 
sections, we (a) present simulation results illustrating how the behavior of length and joint tests follows patterns 
suggested by the geometric framework (b) provided a detailed analysis of test behavior in light of genetic 
architecture and (c) demonstrate two specific ways that the geometric framework can be used to suggest 
modifications to existing rare variant tests of association. 
 
A. Simulation results  
Figure 1 and the overview of the geometric framework in the Methods section suggested that length tests focus 
solely on testing the null hypothesis that there is no difference in the lengths of the two allele frequency vectors, 
namely ‖  ‖   ‖ 
 ‖ , while joint tests focus on testing the null hypothesis that the length of the difference 
between the two allele frequency vectors,  ‖     ‖  is zero. We used simulation to confirm that the behavior of 
these values directly corresponds to the power of both length and joint tests (Figure 2). 
 
B. Analytic insights into test behavior 
Having provided an overview of the geometric framework and suggested intuition behind the behavior of different 
classes (Figure 1), as well as simulation results confirming this intuition (Figure 2), in the following sections we will 
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explicitly demonstrate how genetic architecture affects the behavior of length, angle and joint tests. In particular we 
will explore how the three types of tests behave in relationship to three components of the genetic architecture of 
disease: (1) The relative risk of disease   (          ), where       
    
  , (2) the number of variants, m, in 
the gene and (3) the population minor allele frequencies at the m variant sites,  . 
 
1. Changes in the relative risk distribution 
For low prevalence diseases,   
    , and   
      , where    is the relative risk of site j, and so   >1 denotes a 
site where the rare allele increases disease risk,   <1 denotes a site which reduces disease risk  and   =1 denotes a 




Length tests typically evaluate the difference between  ‖  ‖       ‖ 
 ‖   which is equivalent to comparing 
(∑ | ̂   |
  
   )
 
     (∑ |  |
  
   )
 
  where  ̂  is the MLE of   . If  
    , then,   (          )  (       )     
and so, 
(∑|    |
 
 




  (∑|  |
 
 




       
 
The limitation of length tests described earlier is demonstrated explicitly here, since     is not a necessary 
condition for <eq. 8> to be true. In fact, there are an infinite number of values of   which, for any given  , make 
<eq. 8> true, since <eq. 8> is an underdetermined equation (i.e. <eq. 8> is a single equation with m unknowns, 
namely            for m>1). For example, consider the case where      for all j, and p=1. Then for any    
where ∑   
 
     , <eq. 8> will be approximately true. In particular, if m=2, λ1=1.25 and λ2=0.75, then ∑   
 
      
and, so, <eq. 8> is true. This example demonstrates that, within a gene with multiple variants at similar MAF, there 
will be little difference in  ‖  ‖       ‖ 
 ‖  if the relative risks cancel out because some variants are risk and other 




Generally, a robust rare variant test of association will have the characteristic that the value of its test statistic will 
move farther from the null hypothesis value as |    | increases. However, for length tests the behavior of 
 ‖  ‖    ‖ 
 ‖  as |    | increases is variable. In situations where all variants are risk (     for all j) or all 
variants are protective (              ) the difference in the lengths of ‖ 
 ‖       ‖ 
 ‖ will increase as |    | 
increases. However, in cases where there is a mix of protective and risk variants (some λj are >1 and others are <1), 
the behavior of  ‖  ‖    ‖ 
 ‖  may or may not increase. In particular, if  ‖ 
 ‖    ‖ 
 ‖  then increasing any λj 
will increase the difference in lengths of  ‖  ‖       ‖ 
 ‖ , whereas if  ‖ 
 ‖    ‖ 
 ‖  decreasing any λj will 
increase the difference in lengths of  ‖  ‖       ‖ 
 ‖ . Thus, length tests demonstrate a lack of robustness in the 
presence of mixes of risk and protective variants. 
 
Joint tests 
While length tests illustrate a lack of robustness in the presence of mixes of risk and protective variants, joint tests, 
in testing ‖     ‖     do not have this same limitation. In general,   ‖ 
    ‖   (∑ |     
 




   
 (∑   
 |    |
  
   )
   
, which is true if and only if, 
|    |
 
 |  |
 
   for all j=1,…,m <eq. 9> 
where         , and    can be interpreted as the “risk deviation.”. <Eq. 9> is only true if and only if      for 
all j, alternatively                 which is true if and only if  
    . Thus, a joint test which considers ‖   
  ‖  equals 0 (the null hypothesis value) exactly when the null hypothesis is true. Alternatively, joint tests can be 
interpreted as finding the length of the allele frequency weighted risk deviations since ‖     ‖  ‖  ‖ . 
Implicitly, joint tests, unlike length tests, do not allow risk deviations to cancel out. Furthermore, it is clear from 
<eq.9> that joint tests are robust to mixes of risk and protective variants since the value of ‖     ‖  will increase 
as |    | increases. Figure 2 provides an example of this behavior.  
 
Angle tests 
Our results thus far suggest that handling mixes of protective/risk variants may be problematic for length tests, while 
joint tests more appropriately handle mixes of protective/risk variants. Thus, since joint tests are testing a combined 
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hypothesis which considers both length and angle differences in the vectors (see Methods), this suggests that angle 
tests might be robust to mixes of protective and risk variants. 
 
To test this claim, note that when the null hypothesis (     ) is true, there is no angle between the two vectors 
(   ). When      then       ‖  ‖  ‖ 
 ‖ , or alternately, ∑     
  
    √∑ (    )
  
   
√∑ (  )
  
   . 
But, we note that if     (l > 0; a constant value for all    ) then  
√∑ (    )
  
   
√∑ (  )
  
    √∑ ∑ (    )
 (  )
  
   
 
     √∑ ∑ (  )
 (  )
  
   
 
     √(∑   
  
   )
 
=  (∑   
  
   ). 
Thus, there is no angle between vectors          whenever    , not only when the null hypothesis is true (l=1). 
In general, larger angles will occur as the values of λj become increasingly different (spread out), as will occur when 
there are mixes of risk and protective variants. However, when values of λj are not that different, there will be little 
difference in the angle between the two vectors, even if the values of λj are different than 1. Thus, importantly, sets 
of variants showing consistent levels of risk or consistent levels of protection will yield minimal angles between the 
case and control allele frequency vectors. For example, if all variants in the set had a relative risk of 2 (   ) there 
would be no angle between the two vectors; refer also to Figure 1c. Hence, angle tests, like length, show lack of 
robustness to a plausible scenario for the values of  . 
 
2. Changes in minor allele frequency 
In the previous section, we described how changes to the relative risk distribution impact length, angle and joint 
tests. With these results in mind, we now turn our attention to how changes in the minor allele frequency vector, 
  impact the general behavior of length and joint tests.  
 
Increasing the minor allele frequency,   , at a particular site j, will have different effects on the difference in lengths 
of the case and control allele frequency vectors,  ‖  ‖   ‖ 
 ‖ , depending upon the value of    and the starting 
value of  ‖  ‖   ‖ 
 ‖ . In particular, increasing    for a risk variant (    ) will increase the value of  ‖ 
 ‖  
 ‖  ‖   if  ‖ 
 ‖   ‖ 
 ‖    before the change. Increasing    for a protective variant (    ) will decrease the 
difference in lengths, and when       changing    does not change the difference in lengths.  In contrast, for joint 
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tests, the impact of minor allele frequency,    on ‖     ‖  is straightforward. Simply stated, since ‖ 
    ‖  
= (∑   
 |    |
  
   )
   
, increases to the minor allele frequencies    will always increase the value of ‖ 
    ‖ , 
regardless of  . 
 
3. Number of variants 
For length tests, the impact of increasing the number of variants, m, in the set is straightforward. Simply stated, if the 
length of the case vector ( ‖  ‖ ) is greater than the length of the control vector ( ‖ 
 ‖ ) before adding the 
additional variant, then if the additional variant has   
    
 , the difference in lengths will increase whereas if 
  
    
  the difference in lengths will decrease. The addition of non-causal variants will, on average, increase both 
the case and control vectors a similar amount and, thus, have no impact on the difference in lengths. However, for 
joint tests, the value of ‖     ‖   (∑   
 |    |
  
   )
   
 will increase with the addition of each causal variant 
(    ) and, on average, remain the same for non-causal variants (    ) that are added to the set being tested.  
 
C. Examples of further implications of the geometric framework 
In the previous sections we have described how the geometric framework provides direct insight into the behavior of 
length and joint tests. The geometric framework also suggests alternative rare variant tests of association, with 
predictable behavior. Earlier, we proposed two generalized tests suggested by the geometric framework.  In the 
following two sections we describe the behavior of these tests on simulated data. 
 
1. The impact of the choice of norm, p 
Earlier, we proposed generalized length and joint test statistics, Lp and Jp, which allowed researchers to select any 
positive value, p>0 or , for p. We now explore the behavior of these test statistics as a function of the choice of 
norm, p. 
 
In most realistic situations, a fraction of the m variants will have      since it is difficult to identify, a priori, 
which of the variants in a set are causal (    ). Thus, in the observed sample, many of the estimated relative risks 
will be different from 1 only by chance—not reflecting a population relative risk different than 1. Intuitively, by 
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increasing p, we are able to mitigate the effect of non-causal sites on the test statistic, by, in essence, up-weighting 
larger observed effects. Ultimately, this translates into a mitigation of decreased power from the addition of non-
causal sites, as seen in Figures 3a and 3b for Lp and Jp, respectively. Importantly, we see a complete reversal in the 
ordering of most powerful tests as we move from 0 to 72 non-causal sites for the length test, and a near complete 
reversal for the joint test. 
 
The intuition in Figure 3 can be confirmed by looking more carefully at the formulation of the test statistics. For Jp, 
in all cases, increasing p, means that larger allele frequency weighted risk deviations,   
 | ̂   |
 
, are counted 
proportionally more in    ‖ 
    ‖   (∑   
 | ̂   |
  
   )
   
. For L, a similar result also holds. Consider a 
case where the allele frequency at all variant sites is constant,      for all j. Then,     ‖ 
 ‖   ‖ 
 ‖  
 (  ∑ | ̂ |
  
   )
 
  (   )
 
    (∑ | ̂ |
  
   )
 
   ( )
 
   ((∑ | ̂ |
  
   )
 
  ( )
 
 ). Thus, if all  ̂   , increasing 
p means that variants with larger estimated risk will be counted proportionally more when finding the difference in 
lengths. In situations where f is not constant, the same general result holds, but may be mitigated or exacerbated 
based on the allele frequencies of the non-causal and causal variants. Thus, higher choices of norms exhibit more 
robustness to the inclusion of neutral variants by upweighting larger effects and downweighting weaker effects 
observed in the sample data.  
 
2. Fine-tuned combinations of length and joint tests 
Earlier, we defined (      )    (‖ 
 ‖  ‖ 
 ‖ )
 
 (    )    ‖ 
 ‖  ‖ 
 ‖  (      ( )). Thus,  
 (      ) gives more fine-tuned control over the contribution of length and angle differences to the test statistic. 
Most joint tests implicitly let   =   . Figure 4 illustrates that more powerful tests can be obtained for particular 
relative risks by modifying   . 
 
Discussion 
Observing all variation in large genetic datasets is fast becoming a reality due to high throughput sequencing 
technologies. However, an open question is how to best use these datasets in order to test for association between 
rare variants and phenotypes of interest. The current strategy is to simultaneously analyze multiple rare variants in 
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the same gene in a single statistic, with at least 18 such methods having been proposed to date. While the underlying 
intuition for some tests provides a means for determining which are similar, in other cases it is less obvious how 
they are related. Here, we have derived a formal geometric framework that provides a rigorous method for 
comparing many existing rare variant tests. Further, we have identified strategies to increase statistical power both 
by adjusting features of existing tests and by combining existing tests with different properties.  
 
When placed in context of this geometric framework, we find that the major distinguishing characteristic of rare 
variant tests is how they handle variants with opposing directions of effect. The geometric framework differentiates 
between tests that are robust to a mix of risk and protective variants (joint tests) and those that are most powerful 
when all causal variants have the same direction of effect (length tests). While this distinction was previously known 
to exist, we are now able to attribute the difference in performance to a theoretical difference in the underlying null 
hypotheses of the respective tests. By decomposing the compound null hypothesis of no phenotype association 
within a set of multiple rare variants into simple null hypotheses, it becomes clear that a “rare variant association” 
can be interpreted in different fashions. Namely, a rare variant association can be either a difference between cases 
and controls in the cumulative frequency of all rare alleles as assumed by the length tests, or a pattern of frequency 
differences for individual variants as assumed by the joint tests.  Both definitions of rare variant association are 
entirely reasonable and there are likely to be traits and susceptibility genes that satisfy each definition.  
 
We classified many existing rare variant tests according to the geometric framework, including the most common 
and cited methods; most could be categorized as either a length or a joint test. Thus, despite the number and seeming 
diversity of rare variant tests proposed to date, they are actually quite similar in philosophy. However, we did 
observe some tests which did not obviously fit the geometric framework; for example, Bayesian approaches 
[Quintana et al. 2011; Yi and Zhi 2011], extensions of single-marker methods [Li, Zhang and Yu 2010] and other 
approaches [Wu et al. 2011 with a non-additive kernel]. We do not view the existence of such  methods as a 
limitation of the geometric framework, but rather a dramatic shift in methodology from what has largely been 
developed to date.  If a test satisfies the definition of neither a length nor a joint test, it could benefit the field as it 
would introduce alternative interpretations of the rare variant problem and potentially improve our ability to 




The geometric framework provides several practical applications to rare variant analysis. With performance known 
to differ between tests, however subtly, investigators are likely to apply multiple gene-based tests to the same 
dataset. The geometric classification method can be a useful tool in planning an analysis that includes multiple tests 
on the same set of rare variants. The investigator can choose a set of tests that provide complementary pieces of 
information, for example ensuring both length and joint-style tests are applied. If some prior knowledge of the 
underlying genetic architecture is available, it can inform the set of tests that are likely to perform best.  The 
geometric framework can also aid in the interpretation of the results from multiple rare variant tests. Given that we 
can predict which tests should produce similar p-values based on their classification (length versus joint), 
differences in significance can be attributed to additional factors such as variant weighting schemes, which in turn 
can be valuable for interpreting a significant association signal. For example, frequency-based weights that increase 
significance of a test may provide some information on the underlying frequency spectrum of causal variants. 
Furthermore, tests within each category are likely to perform similarly with respect to artifacts in the data such as 
genotyping errors [Powers et al. 2011; Mayer-Jochimsen et al. 2012] and population stratification [Zawistowski et 
al. 2012].  Thus, methodological research in these areas may not need to consider each of the many rare variant tests 
individually, but rather consider implications within each broad class of tests.  
 
Our exploration of the effect of norms on test power also has implications for rare variant analysis designs. 
Combining multiple rare variants into a single test statistic leads to an inevitable signal to noise problem due to the 
inclusion of non-causal variants. In our analysis, we observed that the value of the norm used to compute distance 
between case and control frequency vectors in a rare variant statistic contributes to the robustness of that statistic to 
the inclusion of non-causal variants in the analysis. We showed that in some cases increasing the norm of the 
statistic can reduce power loss for inclusion of non-causal variants. However, only norms of p=1 and p=2 have been 
used to date, indicating that this is a relatively unexplored aspect of handling the signal to noise problem in rare 
variant testing.  
 
This is noteworthy because the common current strategy for reducing the inclusion of non-causal variants is to 
combine only non-synonymous and nonsense coding variants within a gene since these are assumed to be most 
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likely to be causal. This strategy ignores the potential deleterious effect of non-coding and synonymous variants, 
both of which have been shown in some cases to contribute to disease risk. In particular, the ENCODE database 
highlights the critical role that the non-coding portion of the genome plays in gene expression [ENCODE, 2012]. 
Efficiently incorporating non-coding variation into rare variant tests while controlling for non-causal variants may 
be a powerfully strategy for detecting novel associations.  The increased-norm approach provides an alternative to 
the nonsynonymous-only approach of controlling power loss due to inclusion of non-causal variants with the 
advantage that it allows a more complete set of rare variation in the gene, particularly non-coding variants, to be 
investigated.  
 
The categorization of tests based on assumptions of risk and protective variants helps to systematically explain some 
of the differences in performance between rare variant tests. However, there are likely several additional factors that 
can impact performance, most notably variant weighting strategies.  Weighting rare variants based on some criteria 
of evidence for association is a common strategy to attempt to increase power and includes allele frequency-based 
weights, quantitative predictions of the damaging impact of a variant or a measure of conservation across species. 
Though we have not directly considered it here, the geometric framework can provide a context for evaluating the 
effect of various weighting strategies. The weighted variants can be viewed as transformations of the original 
genotype frequency vectors, and the merits of a weighting strategy could be determined by comparing the change in 
the original and transformed vectors. For example, if we considered weighting strategies for a length test, a set of 
weights would be beneficial if the weighted case and control vectors have a larger difference in normed length than 
did the original unweighted vectors.   
 
The geometric framework presented here provides a rather unique perspective on the current field of rare variant 
association tests. In addition to improving our understanding of why certain tests perform as they do and which are 
methodologically most similar, we have also uncovered areas in which future modifications can be made to existing 
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Table 1. Classifying existing rare variant tests using the geometric framework 
 
1. CMC is a length test when all variants are below an arbitrarily defined MAF threshold; when some variants 




Figure 1. Two-dimensional rendering of the geometric framework for rare variant tests 
The set of graphs shows simplified scenarios for two rare variant sites in a case-control dataset and are designed to 
provide intuition into the geometric interpretation of rare variant tests. 
 
A) The vectors    (  
    
 ) and    (  
    
 ) contain observed allele frequencies at two rare variant sites for 
cases and controls, respectively.  ‖  ‖  and ‖ 
 ‖  indicate the lengths of these frequency vectors with respect to 
the   norm,   is the measure of the angle between    and     and ‖     ‖  is the distance between the endpoints 
of     and   .  The null hypothesis of no rare variant association (    
    ) can be tested using any of the three 
following null hypotheses related to the geometry of the frequency vectors: (i) ‖  ‖  ‖ 
 ‖ , the lengths of the 
vectors are equal, (ii)    , the angle between the vectors is zero, or (iii) ‖     ‖   , the distance between 
the endpoints of the vectors is zero. We refer to tests of the three geometric null hypotheses as, respectively, length, 
angle and joint tests. In the pictured scenario, the minor allele frequency is higher in cases for each variant (  
  
  
        
    
 ), indicating both as potential risk variants.  
 
B) Under the null case of no association (     ) each of the geometric null hypotheses hold: (i) ‖  ‖  
‖  ‖ , (ii)    , and (iii) ‖ 
    ‖   . 
 
C) Both variants are causative with the case vector being a scalar multiple of the control vector (      ). This 
occurs if the case frequency and control frequency are the same across all variant sites. The result is that  ‖  ‖  
‖  ‖  and ‖ 
    ‖   , but the null hypothesis of     still holds. This scenario highlights the reason that 
angle tests are not powerful strategies and underscores why none have been proposed. 
 
D) The scenario in which one rare variant is causative (  
    
 )  and the other is protective (  
    
 ). In this 
case, it is possible that ‖  ‖  ‖ 
 ‖  so that the signals from the two variants effectively cancel each other out, 
explaining reduced performance for length tests in the presence of a mix of risk and protective variants. 




Figure 2. Power of length and joint tests corresponds to the behavior predicted by geometric framework 
 
This graph illustrates the power of length and joint tests in relation to the expected value of the difference in lengths 
or length of difference of    and   . In particular we consider the simplified scenario of a gene containing two rare 
variants, both with an allele frequency of 1%. The sample consists of 1500 cases and 1500 controls. The relative risk 
at the first variant site (λ1) is fixed at 1.25, while the relative risk at the second site (λ2) varies along the x-axis. 
 
We plot the power of power of a length test (CMC) alongside the expected value of  | ‖  ‖   ‖ 
 ‖ |. The 
expected value of the length test statistic will be minimized (taking a value of zero) when the relative risk at site two 
is 0.75. As the relative risk at site two (λ2) moves away from the value 0.75, the expected value of the length test 
statistic increases linearly. A similar pattern of behavior is observed for other length tests (e.g., CMAT and PR) 
though not shown here. We also plot the expected value of  ‖     ‖  along with the power of a joint test (SKAT) 
Unlike length tests, joint tests attain their minimum value when λ2=1, with the value of the expected value of both 
statistics increasing symmetrically as λ2 moves away from 1. A similar pattern of behavior is observed for other joint 





Figure 3. Power of length and joint tests corresponds to the behavior predicted by geometric framework 
 
The two graphs illustrate the power of length (    ‖ 
 ‖   ‖ 
 ‖ )and joint tests (   ‖ 
    ‖ ) with 
different norms (p=1, 2, 4 and ∞). In each case the test statistic is computed and significance is assessed via 
permutation of case-control status. We consider a scenario where a gene contains eight causal risk variants, all with 
a relative risk of 2.0. Two of the risk variants have MAF=1%, the other six have MAF=0.1%. We simulated a 
sample of 1000 cases and 1000 controls for this setting. We then considered 9 additional settings where we added 8, 
16, 24, 32, 40, 48, 56, 64 and 72 additional non-causal variants (relative risk=1), always maintaining 3:1 ratio of low 
MAF (0.1%) to high MAF (1%) variants in the set.  
 
A)  For   , as we move from no non-causal variants to 72 non-causal variants, the order of most powerful tests 
completely reverses, suggesting that higher norms are more optimal in situations with large numbers of non-causal 
variants. 
 
B) For   , as we move from no non-causal variants to 72 non-causal variants, the order of most powerful tests nearly 





Figure 4. Arbitrary combining of length and angle tests 
 
We conducted a simulation analysis and used (      )with p=q=2, and  let   = 1 (length only),    0.75, 
   0.5 (typical joint test),    0.25 and   0 (angle only test). Figure 4 illustrates the power of these five tests 
across different values of λ2. Power curves are as predicted. In particular, the length only (   1) and angle only 
(   0) tests show the least robustness, while the (   0.5) test is quite robust. As expected, the (   0.75) 
weighted test outperforms the (   0.5) test when both variants are risk-inducing, while providing more power than 
the length only test when there is a mix of risk-inducing and protective variants. The reverse is true for the 
(   0.25) test. 
 
